Close Menu

NEW YORK – OpGen said Wednesday after the close of the market that its second quarter revenues grew 28 percent year over year as the company continues to await US Food and Drug Administration clearance for its antimicrobial resistance test.

For the three months ended June 30, the Gaithersburg, Maryland-based firm reported revenues of $1.0 million compared to $788,901 a year ago, on par with the average analyst estimate of $1.0 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

23andMe has a holiday popup shop at a mall and could open additional stores, Bloomberg reports.

By studying koalas and a retrovirus that infects them, researchers may have uncovered a new sort of 'immune response' that occurs at the genomic level, Agence France Presse reports.

NPR reports that the first person in the US given a gene editing-based therapy for a genetic disorder is heading home.

In Science this week: ancient genomes reveal social inequality within individual households, new method for quantifying genetic variation in gene dosage, and more.